Polarean Imaging PLC Transfer of warrants (8245M)
September 24 2021 - 2:00AM
UK Regulatory
TIDMPOLX
RNS Number : 8245M
Polarean Imaging PLC
24 September 2021
Polarean Imaging plc
("Polarean" or the "Company")
Transfer of warrants
Polarean Imaging plc (AIM: POLX), the medical--imaging
technology company, with a proprietary drug--device combination
product using hyperpolarised xenon-129 gas to enhance magnetic
resonance imaging (MRI) in pulmonary medicine, announces that it
has received notification that an aggregate of 2,801,084 warrants
over ordinary shares in the Company, granted between 3 June 2013
and 3 December 2014, (the 'Warrants') have been transferred to
Kenneth West in accordance with the terms of the warrant agreements
pursuant to which they were granted.
Following the transfer of the Warrants, Kenneth West holds a
total of 2,801,084 warrants over ordinary shares of the Company. In
addition, Kenneth also holds options for 2,263,213 shares and
475,594 ordinary shares.
A notification has been made in accordance with the requirements
of the EU Market Abuse Regulation in respect of the PDMRs and
further details can be found by following this link:
https://www.polarean-ir.com/content/investors/shareholder-information
There has been no change to the number of outstanding warrants
over Polarean's Ordinary Shares as a result of this transfer.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Jonathan Allis, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams / Fred Walsh (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 (0)7980 541 893 / +44
(0)7879 741 001
About Polarean ( www.polarean.com )
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue generating, medical drug-device
combination companies operating in the high resolution medical
imaging market.
The Group develops equipment that enables existing MRI systems
to achieve an improved level of pulmonary function imaging and
specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an
imaging agent to visualise ventilation and gas exchange regionally
in the smallest airways of the lungs, the tissue barrier between
the lung and the bloodstream and in the pulmonary vasculature.
Xenon gas exhibits solubility and signal properties that enable it
to be imaged within other tissues and organs.
In October 2020, the Group submitted a New Drug Application
("NDA") to the FDA for hyperpolarised (129) Xe used to evaluate
pulmonary function and to visualise the lung using MRI. In December
2020, the Group received confirmation of acceptance of its NDA by
the FDA, with a target PDUFA action date of 5 October 2021.
The Group operates in an area of significant unmet medical need
and the Group's technology provides a novel diagnostic approach,
offering a non-invasive and radiation-free functional imaging
platform which is more accurate and less harmful to the patient
than current methods. The annual burden of pulmonary disease in the
US is estimated to be over US$150 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHLJMFTMTJTBIB
(END) Dow Jones Newswires
September 24, 2021 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Apr 2023 to Apr 2024